[NFS-01] Neuroscience Frontier Symposium 01
New approaches aimed for the development of disease modifying therapies of Alzheimer's disease and other dementia diseases

[NFS-01-3] HMW Aβ oligomers are important targets for disease modifying approach of Alzheimer's disease

^○Kenjiro Ono (Division of Neurology, Department of Medicine, School of Medicine, Showa University, Japan)

Alzheimer's disease (AD) is the most common neurodegenerative disorder and affects over 40 million patients worldwide, but no causative or preventive treatment is currently available. However, recent researches have gradually elucidated new pathogenesis of AD and other dementia disease, and researches linking to disease modification therapies (DMTs) are also progressing. In this symposium, we introduce cutting-edge approaches for DMTs development of AD and other demnetia diseases, and discuss their translational possibilities and issues to be resolved.

Education
1997 M.D. Showa University School of Medicine
2002 Ph.D. Kanazawa University Graduate School of Medical Science

Research and Professional Experience:
2007-2009Postdoctoral Scholar, Department of Neurology, David Geffen School of Medicine, UCLA
2009-2011Instructor, Department of Neurology, Kanazawa University Hospital
2011-2015Associate Professor, Department of Neurology, Neurobiology and Aging,
Kanazawa University Graduate School of Medical Science
2015-presentProfessor, Department of Neurology, Showa University School of Medicine

Awards and Honors:
2010The Award of Showa University School of Medicine Alumni Association
2013 　　　　10th Kanazawa University Medical Award
2015Japanese Society of Neurology Award
2016Medical Research Encouragement Prize of The Japan Medical Association
The Award for Distinguished Investigator of Japanese Society for Neurochemistry
2017　　　　 Japanese Society of Neurological Therapeutics Award
Kazato Prize (Kazato Research Foundation)